Biodesix Awarded Advanced Diagnostic Laboratory Test Status For Its Nodify CDT Test By The Center For Medicare And Medicaid Services
Portfolio Pulse from Happy Mohamed
Biodesix, Inc. (NASDAQ:BDSX) has been awarded Advanced Diagnostic Laboratory Test (ADLT) status for its Nodify CDT Test by the Centers for Medicare & Medicaid Services (CMS), effective June 30, 2023. The Nodify CDT test, used in combination with the Nodify XL2 test, helps physicians assess the risk of malignancy of pulmonary nodules. The payment amount for the Nodify CDT test as established by the Medicare Administrative Contractor is $649.
July 06, 2023 | 1:11 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Biodesix's Nodify CDT Test has been awarded ADLT status by CMS, which is a recognition of the test's clinical value and uniqueness. This could potentially increase the company's revenue as the payment amount for the test is $649.
The award of ADLT status to Biodesix's Nodify CDT Test by CMS is a significant recognition of the test's clinical value and uniqueness. This could potentially increase the company's revenue as the payment amount for the test is $649. Therefore, this news is likely to have a positive impact on the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100